EUCTR2019-002351-42-PL进行中（未招募）1 期
An Observational, Follow-on Study to the MEDI4920 (D5100C00002) Study to Evaluate the Duration of Clinical and Pharmacodynamic Efficacy of 12 weeks of Treatment with VIB4920 in Subjects with Moderate to Severe Rheumatoid Arthritis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participants are eligible to be included in this study only if all of the following criteria apply:
- •1. Have successfully completed the 12-week treatment period and the follow-up period of the MEDI4920 D5100C00002 study and received treatment with 1000 mg or 1500 mg of VIB4920 at sites 2002456 and 2002205 in Poland.
- •2. Are willing and able to provide written informed consent and any locally required authorisation (e.g., European Union [EU] Data Privacy Directive in the EU) prior to undergoing any protocol-related procedures.
- •3. Are willing and able to comply with the protocol and complete all study assessments.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 17
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
尚未招募
不适用
An observational study to assess the status of Meda dhatu in individuals sleeping during daytimeCTRI/2021/10/037616Dr Archana Vishnu Khilare
进行中（未招募）
1 期
A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.Serious respiratory syncytial virus (RSV) diseaseMedDRA version: 7.0Level: PTClassification code 10061603EUCTR2004-000039-27-ISMedImmune, Inc.5,750
进行中（未招募）
不适用
A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.Serious respiratory syncytial virus (RSV) diseaseMedDRA version: 7.0Classification code 10061603EUCTR2004-000039-27-SEMedImmune, Inc.6,600
进行中（未招募）
不适用
A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.Serious respiratory syncytial virus (RSV) diseaseMedDRA version: 7.0Level: PTClassification code 10061603EUCTR2004-000039-27-CZMedImmune, Inc.6,500
进行中（未招募）
不适用
A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.Serious respiratory syncytial virus (RSV) diseaseMedDRA version: 7.0Level: PTClassification code 10061603EUCTR2004-000039-27-HUMedImmune, Inc.5,750